Travere Therapeutics Inc [TVTX] stock is trading at $8.61, up 7.09%. An important factor to consider is whether the stock is rising or falling in short-term value. The TVTX shares have gain 10.53% over the last week, with a monthly amount glided 4.24%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, Travere Therapeutics to Present at Upcoming Investor Conferences. In a post published today on Yahoo Finance, Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming investor conferences in March:.
From an analyst’s perspective:
Travere Therapeutics Inc [NASDAQ: TVTX] stock has seen the most recent analyst activity on December 05, 2023, when Citigroup upgraded its rating to a Buy and also boosted its price target to $10 from $7. Previously, Citigroup started tracking the stock with Neutral rating on November 20, 2023, and set its price target to $7. On September 22, 2023, downgrade downgraded it’s rating to Equal Weight and revised its price target to $8 on the stock. William Blair downgraded its rating to a Mkt Perform. JP Morgan started tracking with a Overweight rating for this stock on July 21, 2023, and assigned it a price target of $26.
Travere Therapeutics Inc [TVTX] stock has fluctuated between $5.25 and $23.17 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $8.61 at the most recent close of the market. An investor can expect a potential return of 225.2% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
Travere Therapeutics Inc [NASDAQ:TVTX] reported sales of 198.84M for the trailing twelve months, which represents a drop of -19.35%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -1.71%, Pretax Profit Margin comes in at -1.76%, and Net Profit Margin reading is -0.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.57 and Total Capital is -0.56. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.9.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.26 points at the first support level, and at 7.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.81, and for the 2nd resistance point, it is at 9.00.
Travere Therapeutics Inc [TVTX] reported earnings per share of -$1.18 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.27/share, meaning a difference of $0.09 and a surprise factor of 7.10%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $1.97 per share as compared to estimates of -$0.14 per share, a difference of $2.11 representing a surprise of 1,507.10%.
Ratios To Look Out For
For context, Travere Therapeutics Inc’s Current Ratio is 3.47. On the other hand, the Quick Ratio is 3.41, and the Cash Ratio is 0.33. Considering the valuation of this stock, the price to sales ratio is 3.30, the price to book ratio is 3.23.
Transactions by insiders
Recent insider trading involved Dube Eric M, CHIEF EXECUTIVE OFFICER, that happened on Feb 01 ’24 when 19122.0 shares were sold. SVP, GC & CORPORATE SECRETARY, REED ELIZABETH E completed a deal on Feb 01 ’24 to sell 4764.0 shares. Meanwhile, SENIOR VICE PRESIDENT, R&D ROTE WILLIAM E. sold 4764.0 shares on Feb 01 ’24.
